H.R. 672 · 113th Congress
Prescription Drug Abuse Prevention and Treatment Act of 2013
Key: what the circles and colors mean
Each circle is a bill. The ring fills as it moves through Congress:
Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.
Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.
Never voted on. It didn't reach a floor vote before the 113th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.
D
RahallSponsorNo cosponsors.
Prescription Drug Abuse Prevention and Treatment Act of 2013 - Amends the Public Health Service Act to direct the Administrator of the Substance Abuse and Mental Health Services Administration to award grants to states and nonprofit entities for consumer education about opioid abuse, including methadone abuse.
What it does: CRS summary · Introduced in House · Feb 13, 2013
Prescription Drug Abuse Prevention and Treatment Act of 2013 - Amends the Public Health Service Act to direct the Administrator of the Substance Abuse and Mental Health Services Administration to award grants to states and nonprofit entities for consumer education about opioid abuse, including methadone abuse.
Amends the Controlled Substances Act to: (1) set forth training requirements for practitioners registered to prescribe or dispense methadone or other opioids, and (2) require each registered opioid treatment clinic to make acceptable arrangements for each patient who is restricted from having a take-home dose of a controlled substance related to treatment to receive a dose of that substance under appropriate supervision when the clinic is closed.
Prohibits any individual or entity (except hospitals that provide direct patient supervision) from prescribing or dispensing a 40-mg diskette of methadone unless such prescription or dispensation is consistent with the current Drug Enforcement Administration (DEA) methadone policy, until the date the Controlled Substances Clinical Standards Commission: (1) publishes dosing guidelines for methadone, and (2) finds that such 40-mg diskettes are safe and clinically appropriate. Requires the Secretary of Health and Human Services (HHS) to establish such Commission to develop and publish guidelines related to methadone use, including safe dosing guidelines for all forms of methadone and benchmark guidelines for the reduction of methadone abuse.
Requires states receiving controlled substances monitoring program grants to: (1) provide information, upon request, to drug enforcement officials relating to an individual who is the subject of an active drug-related investigation; and (2) require opioid-related deaths to be reported to the Administrator.
Directs the Administrator to develop a Model Opioid Treatment Program Mortality Report.
Requires the Administrator to establish and implement, through the National Center for Health Statistics, a National Opioid Death Registry to track opioid-related deaths.
Requires the Secretary, acting through the Director of the Agency for Healthcare Research and Quality (AHRQ), to require the development and application of specific prescription drug abuse prevention and treatment quality measures for each relevant health care provider setting.
Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov
About this bill and sources
Official title: Prescription Drug Abuse Prevention and Treatment Act of 2013
Latest action (Apr 8, 2013): Referred to the Subcommittee on Crime, Terrorism, Homeland Security, And Investigations.
Policy area: Health · Origin: House · Introduced: Feb 13, 2013
Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)
No recorded floor vote found.